Thyroid cancer survival in Spain stands at about 90%. In 2026, the country is expected to record 6,678 new diagnoses, information from estimates cited by the Asociación Española de Cáncer de Tiroides, or AECAT. The association says treatment results should also track patients’ physical and emotional wellbeing after surgery.
Women will account for most cases. Figures from SEOM and REDECAN, cited by AECAT, put diagnoses among women at 4,941, compared with 1,738 among men. Thyroid cancer represents 13.4% of cancers diagnosed between the ages of 20 and 39. REDECAN projects 301 884 new cancer diagnoses of all types in Spain during 2026, including about 16 432 cases among people younger than 45.
The association has presented a ten-point programme through its campaign ‘Avances que cambian vidas’. Its central complaint is practical: scientific and technological progress has limited value when patients still face avoidable complications and weak follow-up. Support after initial treatment can also be inadequate.
The operation can shape the rest of a patient’s life.
Most patients undergo partial or total thyroidectomy. Complete removal of the gland requires lifelong hormone replacement with daily levothyroxine and regular TSH monitoring. After cancer treatment, the target TSH level may initially be set lower, then reconsidered if follow-up remains favourable. Surgery can also affect structures that require continued monitoring. AECAT so wants the type of operation selected carefully, using evaluated technologies and protocols to protect the parathyroid glands and other impressive structures.
Modern high-resolution ultrasound and fine-needle aspiration, alongside molecular testing and pathology, can help assess how aggressive a thyroid nodule is. These tools can also distinguish patients who may need surgery from those for whom surveillance or another approach may be appropriate. This supports AECAT’s argument for individual decisions on the extent of surgery instead of automatic total thyroidectomy. Registry evidence among younger men adds weight to the case, since treatment consequences can last for decades.
That focus matters when symptoms continue after surgery. Hypoparathyroidism can add to physical and cognitive burdens, as well as treatment needs. AECAT says complications should be prevented where possible, detected early and treated properly. Patients with continuing difficulties should have access to specialised teams.
Published clinical materials describe anxiety and depression among the possible effects. They also point to reduced physical activity. So-called brain fog can be another problem, as can difficulty remaining in work. About 80% of people with chronic hypoparathyroidism are women, and roughly one-third may be unable to work. A return to ordinary routines is so a clinical outcome, not a social extra.
AECAT’s proposal reaches beyond the operating theatre. It calls for coordinated care involving surgery and endocrinology. Oncology and nuclear medicine can join the team, alongside basic care. Nursing and mental health services can also be involved, with other specialties added when necessary. The association wants care to continue after the first treatment phase because some needs remain for months or years.
Follow-up should include endocrine review and assessment of calcium and phosphate balance. It should also cover kidney function and hormone adjustment, alongside cognitive or psychological symptoms. The practical test is whether the system catches long-term complications before they become part of a patient’s daily routine.
Clear information is another central demand. Patients should receive understandable explanations at each stage of treatment so they can weigh alternatives and take part in decisions about their health. Psychological care should begin at diagnosis and remain available through follow-up, not be treated as an optional extra.
The need is visible even when no detectable disease remains. Fear of recurrence and fatigue can obstruct a return to normal routines. Difficulty maintaining hormonal balance and chronic after-effects can do the same. AECAT wants those problems recorded alongside cancer control.
Access to new idea sits within a wider European debate over how quickly new treatments reach patients. For thyroid cancer, AECAT points to molecular tests and targeted therapies, while seeking access to new surgical technologies and future treatments. Its position is that clinical need should guide access before a patient’s condition deteriorates severely.
Research remains part of the programme. AECAT is asking for continued work on disease biomarkers and prognostic factors. It also wants patients’ experience to influence research priorities and care pathways, as well as the way results are assessed.
Published clinical materials describe wider consequences of chronic hypoparathyroidism. Disrupted calcium and phosphate balance can affect bones and kidneys, as well as the nervous system. Possible effects include neuromuscular symptoms and renal complications. Cognitive problems and tissue calcification are also possible. Follow-up so needs more than a calcium test: it should include phosphate and magnesium, along with kidney function, symptoms and quality of life.
For Spain’s 2026 thyroid cancer estimates, REDECAN data put new diagnoses among men at 1,738. The registry analysis found that incidence among men aged 20 to 49 rose by approximately 4% annually between 1993 and 2018.
